OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trial
Fuxiang Wang, Wen Xiao, Yimin Tang, et al.
The Lancet Regional Health - Western Pacific (2023) Vol. 38, pp. 100835-100835
Open Access | Times Cited: 24
Fuxiang Wang, Wen Xiao, Yimin Tang, et al.
The Lancet Regional Health - Western Pacific (2023) Vol. 38, pp. 100835-100835
Open Access | Times Cited: 24
Showing 24 citing articles:
Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19
Bin Cao, Yeming Wang, Hongzhou Lu, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 3, pp. 230-241
Open Access | Times Cited: 59
Bin Cao, Yeming Wang, Hongzhou Lu, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 3, pp. 230-241
Open Access | Times Cited: 59
Deuremidevir and Simnotrelvir–Ritonavir for the Treatment of COVID-19
Ke‐Wei Zhu
ACS Pharmacology & Translational Science (2023) Vol. 6, Iss. 9, pp. 1306-1309
Open Access | Times Cited: 24
Ke‐Wei Zhu
ACS Pharmacology & Translational Science (2023) Vol. 6, Iss. 9, pp. 1306-1309
Open Access | Times Cited: 24
On the origins of SARS-CoV-2 main protease inhibitors
Yves L. Janin
RSC Medicinal Chemistry (2023) Vol. 15, Iss. 1, pp. 81-118
Closed Access | Times Cited: 15
Yves L. Janin
RSC Medicinal Chemistry (2023) Vol. 15, Iss. 1, pp. 81-118
Closed Access | Times Cited: 15
Inhibitors of SARS-CoV-2 Main Protease (Mpro) as Anti-Coronavirus Agents
Agnieszka Zagórska, Anna Czopek, Monika Fryc, et al.
Biomolecules (2024) Vol. 14, Iss. 7, pp. 797-797
Open Access | Times Cited: 6
Agnieszka Zagórska, Anna Czopek, Monika Fryc, et al.
Biomolecules (2024) Vol. 14, Iss. 7, pp. 797-797
Open Access | Times Cited: 6
Non-peptidic inhibitors targeting SARS-CoV-2 main protease: A review
Ya-Qi Xiao, Jiao Long, Shuang‐Shuang Zhang, et al.
Bioorganic Chemistry (2024) Vol. 147, pp. 107380-107380
Closed Access | Times Cited: 5
Ya-Qi Xiao, Jiao Long, Shuang‐Shuang Zhang, et al.
Bioorganic Chemistry (2024) Vol. 147, pp. 107380-107380
Closed Access | Times Cited: 5
3-Chymotrypsin-like Protease (3CLpro) of SARS-CoV-2: Validation as a Molecular Target, Proposal of a Novel Catalytic Mechanism, and Inhibitors in Preclinical and Clinical Trials
Vitor Martins de Freitas Amorim, Eduardo Pereira Soares, Anielle Salviano de Almeida Ferrari, et al.
Viruses (2024) Vol. 16, Iss. 6, pp. 844-844
Open Access | Times Cited: 5
Vitor Martins de Freitas Amorim, Eduardo Pereira Soares, Anielle Salviano de Almeida Ferrari, et al.
Viruses (2024) Vol. 16, Iss. 6, pp. 844-844
Open Access | Times Cited: 5
Optimization of SARS-CoV-2 Mpro Inhibitors by a Structure-Based Multilevel Virtual Screening Method
Lanlan Jing, Fabao Zhao, Lin Zheng, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 670-670
Open Access
Lanlan Jing, Fabao Zhao, Lin Zheng, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 670-670
Open Access
Efficacy and safety of SHEN26, a novel oral small molecular RdRp inhibitor for COVID-19 treatment: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial
Jiangtao Bai, Tetsuya Asakawa, Wenfang Yuan, et al.
Virology Journal (2025) Vol. 22, Iss. 1
Open Access
Jiangtao Bai, Tetsuya Asakawa, Wenfang Yuan, et al.
Virology Journal (2025) Vol. 22, Iss. 1
Open Access
Identification of novel small-molecule inhibitors of SARS-CoV-2 by chemical genetics
Chris Chun-Yiu Chan, Qian Guo, Jasper Fuk‐Woo Chan, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 9, pp. 4028-4044
Open Access | Times Cited: 4
Chris Chun-Yiu Chan, Qian Guo, Jasper Fuk‐Woo Chan, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 9, pp. 4028-4044
Open Access | Times Cited: 4
Bioengineered amyloid peptide for rapid screening of inhibitors against main protease of SARS-CoV-2
Dongtak Lee, Hyo Gi Jung, Dongsung Park, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 3
Dongtak Lee, Hyo Gi Jung, Dongsung Park, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 3
Progress in Research on Inhibitors Targeting SARS-CoV-2 Main Protease (Mpro)
Yue Yang, Yidan Luo, Chenbo Zhang, et al.
ACS Omega (2024) Vol. 9, Iss. 32, pp. 34196-34219
Open Access | Times Cited: 3
Yue Yang, Yidan Luo, Chenbo Zhang, et al.
ACS Omega (2024) Vol. 9, Iss. 32, pp. 34196-34219
Open Access | Times Cited: 3
Epigenetic regulation of human FOXP3+ Tregs: from homeostasis maintenance to pathogen defense
Yi Yue, Yuqing Ren, Chunya Lu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Yi Yue, Yuqing Ren, Chunya Lu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Evaluation of inhibition effect and interaction mechanism of antiviral drugs on main protease of novel coronavirus: Molecular docking and molecular dynamics studies
Xin Gao, Cuihong Wang, Yue Jiang, et al.
Journal of Molecular Graphics and Modelling (2024) Vol. 133, pp. 108873-108873
Closed Access | Times Cited: 2
Xin Gao, Cuihong Wang, Yue Jiang, et al.
Journal of Molecular Graphics and Modelling (2024) Vol. 133, pp. 108873-108873
Closed Access | Times Cited: 2
Small-molecule anti-COVID-19 drugs and a focus on China’s homegrown mindeudesivir (VV116)
Qiuyu Cao, Yi Ding, Yu Xu, et al.
Frontiers of Medicine (2023) Vol. 17, Iss. 6, pp. 1068-1079
Closed Access | Times Cited: 7
Qiuyu Cao, Yi Ding, Yu Xu, et al.
Frontiers of Medicine (2023) Vol. 17, Iss. 6, pp. 1068-1079
Closed Access | Times Cited: 7
Unraveling the structural and functional dimensions of SARS-CoV2 proteins in the context of COVID-19 pathogenesis and therapeutics
Aniruddh Jhanwar, Dipika Sharma, Uddipan Das
International Journal of Biological Macromolecules (2024) Vol. 278, pp. 134850-134850
Closed Access | Times Cited: 1
Aniruddh Jhanwar, Dipika Sharma, Uddipan Das
International Journal of Biological Macromolecules (2024) Vol. 278, pp. 134850-134850
Closed Access | Times Cited: 1
Advances in the Search for SARS-CoV-2 Mpro and PLpro Inhibitors
Marcel Arruda Diogo, Augusto Gomes Teixeira Cabral, Renata Barbosa de Oliveira
Pathogens (2024) Vol. 13, Iss. 10, pp. 825-825
Open Access | Times Cited: 1
Marcel Arruda Diogo, Augusto Gomes Teixeira Cabral, Renata Barbosa de Oliveira
Pathogens (2024) Vol. 13, Iss. 10, pp. 825-825
Open Access | Times Cited: 1
A validated LC-MS/MS method for determination of six Anti-SARS-CoV-2 drugs in plasma and its application for a pharmacokinetic study in rats
Zongliang Xu, Chengjian Li, Xian Qian, et al.
Journal of Chromatography B (2024) Vol. 1235, pp. 124038-124038
Closed Access
Zongliang Xu, Chengjian Li, Xian Qian, et al.
Journal of Chromatography B (2024) Vol. 1235, pp. 124038-124038
Closed Access
Adverse drug reactions associated with COVID-19 management
Vivek P. Chavda, Payal Dodiya, Vasso Apostolopoulos
Naunyn-Schmiedeberg s Archives of Pharmacology (2024) Vol. 397, Iss. 10, pp. 7353-7376
Closed Access
Vivek P. Chavda, Payal Dodiya, Vasso Apostolopoulos
Naunyn-Schmiedeberg s Archives of Pharmacology (2024) Vol. 397, Iss. 10, pp. 7353-7376
Closed Access
19F qNMR based pharmacokinetics, metabolism and mass balance studies of SARS-CoV-2-3CL protease inhibitor simnotrelvir (SIM0417) in humans
Zeyu Wang, Yong-Mei Ren, Shu-Wei Hu, et al.
Acta Pharmacologica Sinica (2024)
Closed Access
Zeyu Wang, Yong-Mei Ren, Shu-Wei Hu, et al.
Acta Pharmacologica Sinica (2024)
Closed Access
Discovery of peptidomimetic spiropyrrolidine derivatives as novel 3CLpro inhibitors against SARS-CoV-2
Samuel Desta Guma, Zhaoyin Zhou, Kang Song, et al.
European Journal of Medicinal Chemistry (2024) Vol. 281, pp. 117004-117004
Closed Access
Samuel Desta Guma, Zhaoyin Zhou, Kang Song, et al.
European Journal of Medicinal Chemistry (2024) Vol. 281, pp. 117004-117004
Closed Access
Design, synthesis, and biological evaluation of dithiocarbamate derivatives as SARS-CoV-2 Mpro inhibitors
Jin-Qi Peng, Ya-Qi Xiao, Jiao Long, et al.
Bioorganic & Medicinal Chemistry Letters (2024) Vol. 114, pp. 130011-130011
Closed Access
Jin-Qi Peng, Ya-Qi Xiao, Jiao Long, et al.
Bioorganic & Medicinal Chemistry Letters (2024) Vol. 114, pp. 130011-130011
Closed Access
Nirmatrelvir, SIM0417, and RAY1216: potent and selective SARS-CoV-2 main protease inhibitors for the potential treatment of COVID-19
Ahmed A. Al‐Karmalawy
Elsevier eBooks (2024), pp. 351-356
Closed Access
Ahmed A. Al‐Karmalawy
Elsevier eBooks (2024), pp. 351-356
Closed Access
Development of pyrimidone derivatives as nonpeptidic and noncovalent 3-chymotrypsin-like protease (3CLpro) inhibitors with anti-coronavirus activities
Fan Pan, Qifan Zhou, Ming Yan, et al.
Bioorganic Chemistry (2024) Vol. 154, pp. 107988-107988
Closed Access
Fan Pan, Qifan Zhou, Ming Yan, et al.
Bioorganic Chemistry (2024) Vol. 154, pp. 107988-107988
Closed Access
Drug-drug interactions of simnotrelvir/ritonavir: an open-lable, fixed-sequence, two-period clinical trial
Panpan Ye, Bu‐Fan Yao, Yang Yang, et al.
Clinical Microbiology and Infection (2024)
Open Access
Panpan Ye, Bu‐Fan Yao, Yang Yang, et al.
Clinical Microbiology and Infection (2024)
Open Access
